*Joerg Krueger’s and Stacey Marjerrison’s presentation slides not included
Presentation Description:
Chimeric antigen receptor T cell therapy (CAR T) has shown encouraging results in patients with refractory and relapsed ALL and will soon be available in Ontario. This workshop will: 1) Examine the current state of CAR-T cell trial access in Ontario; 2) Provide an overview of the CAR-T cell program at the Hospital for Sick Children, which is set to be operational in late 2018; 3) Discuss the out of country review process for patients who do not qualify for the CAR-T cell therapy trial at the Hospital for Sick Children; and 4) explain the intake process and experience of patients and families who travel to Children’s Hospital of Philadelphia for this treatment.
Speakers:
Joerg Krueger, MD (slides unavailable)
Staff Physician, Department of Haematology/Oncology
The Hospital for Sick Children
Assistant Professor
University of Toronto
Project Investigator
Research Institute
Dr. Krueger obtained his medical degree from Humboldt University, Berlin, Germany. He completed his doctoral thesis at Humboldt and a post-doctoral fellowship at the Scripps Research Institute, La Jolla, California, with a research focus on cancer immunotherapies.
After finishing his pediatric residency at the Charité University Hospital, Berlin, he did a fellowship in the Department of Hematology and Oncology at The Hospital for Sick Children, Toronto. He was recruited as full-time staff to The Hospital for Sick Children and Assistant Professor at the University of Toronto in 2015 and is part of the Hematopoietic Stem Cell Transplantation and Cellular Therapy/Apheresis team.
Colleen Callahan, RN, MSN, CRNP
Nurse Practitioner, Division Of Oncology
Children’s Hospital of Philadelphia
Colleen Callahan, MSN, CRNP, has worked in pediatric oncology for 23 years, 18 of which as a nurse practitioner in the Oncology Division at Children’s Hospital of Philadelphia. She has worked in the Cancer Immunotherapy Program for the past five years caring for patients pre, during, and post CAR T-cell therapy in the outpatient setting. She follows these patients from their initial referral to the cancer immunotherapy team, through their T cell collection, T cell infusion, and then after infusion monitoring for side effects, adverse events, and long-term effects and responses.
Stacey Marjerrison, MD, MSc, FRCPC (slides unavailable)
Pediatric Hematologist/Oncologist
AfterCare Program Medical Director
McMaster Children’s Hospital
Assistant Professor of Pediatrics
McMaster University
Dr. Stacey Marjerrison is a pediatric oncologist and the Director of the AfterCare Program at McMaster Children’s Hospital. Dr. Marjerrison’s areas of interest are in supportive care for children with cancer and in the interaction between socio-demographic determinants of health and malignancy. Broadly, her work focuses on provision of care for marginalized populations, including Indigenous children in Canada and for all children in low-income countries. As applied to survivors of childhood cancer, this includes building care programs that encourage survivors to engage in healthy active lifestyles.
Dr. Marjerrison is an inaugural member of the Adoptive T-cell Immunotherapy Review Panel of the Ministry of Health and Long-term Care of Ontario and Cancer Care Ontario.
